Product Name: Met (1233-1239) pS1236
Product Number: PE-04AAX90
Size: 200 µg      Price:37.00
1 mg      $US74.00
Peptide Name: Met (1233-1239) pS1236

Product Use: Services as a blocking peptide for use with the Met-pS1236 rabbit polyclonal antibody (Cat. No.: AB-PK705) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. S1236 phosphorylation stimulates phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: EYY-pS-VHN

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1206.1 +1164.1 Da

Peptide Purity Percent after Synthesis and Purification: >90

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: Met - pS1236 phosphosite-specific antibody (Cat. No.: AB-PK705)

Scientific Background: Met (HGFR) is a protein-tyrosine kinase of the TK group and Met family. It is activated by binding hepatocyte growth factor (HGF), which induces dimerization and autophosphorylation. Phosphorylation of Y1003 increases phosphotransferase activity and induces interaction with Cbl. Phosphorylation of Y1230 and Y1235 increases phosphotransferase activity. Phosphorylation of Y1234 increases phosphotransferase activity and induces interaction with Grb2. Phosphorylation of S985 inhibits phosphotransferase activity. Phosphorylation of Y1349 inhibits phosphotransferase activity, but induces interaction with FAK, Gab1, Grb2, Met, PIK3R1, PLCG1 and Src. Met mediates scattering, proliferation, survival, and morphogenesis of cells. Some immediate regulators that bind to Met after activation with HGF include PLCG1, PIK3R1, GRB2, SRC, STAT3 or the adapter GAB1. Met is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. Hepatocellular carcinoma (HCC) occurs with higher risk in those that have chronic HCV (hepatitis C virus) or HBV (hepatitis B virus) infection, or aflatoxin exposure in diet, or alcohol-induced cirrhosis, or another form of cirrhosis.